NCT06876675View on ClinicalTrials.gov

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Enrolling by invitationOBSERVATIONAL
Enrollment

167

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

August 31, 2029

Conditions
Non-Small Cell Lung CancerHyperlipidemia
Interventions
DRUG

Lorlatinib

To study hyperlipidemia frequency, levels, impact on cardiovascular events after use of Lorlatinib in NSCLC patients.

Trial Locations (1)

Unknown

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Peking University Third Hospital

OTHER